Skip to main content

Cannabidiol Safe, May Lower Anxiety in Advanced Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 20, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 20, 2024 -- For patients with advanced breast cancer and baseline clinical anxiety, cannabidiol (CBD) is safe and may reduce anxiety levels two to four hours after ingestion, according to a study published online Dec. 16 in JAMA Network Open.

Manan M. Nayak, Ph.D., from the Dana-Farber Cancer Institute in Boston, and colleagues randomly assigned 50 patients with advanced breast cancer and baseline clinical anxiety to receive oral CBD 400 mg (25 patients) or placebo (25 patients) within 48 hours before a scan assessing tumor burden.

The researchers found that the primary end point of change scores on the afraid subscale of the Visual Analog Mood Scale (VAMS) before and two to four hours after ingestion was numerically greater in the CBD arm, but did not differ significantly between the arms. Significantly lower VAMS afraid T-scores were seen for participants receiving CBD versus placebo when comparing anxiety levels two to four hours after study drug ingestion. There were no reports of grade 3 or 4 toxic effects.

"This preliminary randomized clinical trial establishes CBD as a treatment for anxiety for patients with breast cancer and has laid groundwork for a larger, more definitive trial to test the efficacy of oral CBD, 400 mg, in decreasing anxiety in this patient population," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Low-to-Moderate Agreement Seen for Diagnosing Breast Cancer-Related Lymphedema

THURSDAY, April 24, 2025 -- Different measurement tools and diagnostic criteria show low-to-moderate agreement for diagnosing breast cancer-related lymphedema (BCRL), according to...

Patients Mainly Prefer AI as Second Reader for Screening Mammogram

WEDNESDAY, April 23, 2025 -- Use of artificial intelligence (AI) as a second reader in screening mammography is accepted by patients, according to a study published online April...

Breast Cancer Outcomes Improved With History of Screening Mammography

MONDAY, April 21, 2025 -- Prior screening mammography is associated with earlier stage at breast cancer diagnosis and lower breast cancer mortality, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.